Physician profile
Barbara Allis
NPI 1659386324
$2,532.80
in general payments reported to CMS, 2019-2025
11 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $150 · 2021: $157 · 2022: $417 · 2023: $240 · 2024: $238 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.10 |
| Education | $111.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.57 | 2022-2025 | Botox |
| Teva Pharmaceuticals USA, INC. | $454.51 | 2019 | |
| Boston Scientific Corporation | $363.05 | 2019-2020 | |
| Allergan, INC. | $174.46 | 2021-2022 | |
| Abbott Laboratories | $167.15 | 2025 | Jot Dx |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Symbravo |
| Emd Serono, INC. | $117.56 | 2022 | |
| Acorda Therapeutics, INC | $108.00 | 2019 | |
| Lilly USA, LLC | $100.00 | 2019 | |
| Medtronic USA, INC. | $53.34 | 2020 | |
| Argenx US, INC. | $40.16 | 2025 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Allis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.